[Therapeutic prospects of angiogenesis inhibitors in cancerology].
Bout
J C
JC
CNRS EP-560, Institut de Biologie de Lille.
Soncin
F
F
Vandenbunder
B
B
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D010446:Peptide Fragments; D011480:Protease Inhibitors; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen; C100342:marimastat